wound healing

The company is also pushing ahead with a microRNA-replacement therapy that is designed to improve patient response to colon cancer treatment.

Despite encouraging preclinical safety and efficacy data for its RNAi-based hepatitis C treatment, Somagenics has decided to step back from its previous plan to push the agent into phase I testing this year as it waits to see how more advanced small-molecule therapies fare in lat

Sirnaomics could begin phase I testing of its siRNA-based wound-healing drug candidate STP-705 as soon as next year and expects to run the trial in China, a company official told Gene Silencing News this week.

By Doug Macron
The National Institutes of Health last month handed out nearly $1.3 million in grant funding to support four research projects focused on developing siRNA-delivery technologies.

The drug, STP705, uses a polymeric nanoparticle to enhance topical delivery of siRNAs targeting the TGF-beta 1 and Cox-2 genes to open wounds, Sirnaomics said.

Doing so, however, will require the company to secure additional funding, and it is currently evaluating its options, a company official said.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.